Breast Cancer Research and Treatment

, Volume 123, Issue 2, pp 463–469 | Cite as

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

  • H. Wildiers
  • C. Fontaine
  • P. Vuylsteke
  • M. Martens
  • J. L. Canon
  • W. Wynendaele
  • C. Focan
  • J. De Greve
  • P. Squifflet
  • R. Paridaens
Clinical trial


The aim of this study is to test the hypothesis that antiangiogenic treatment with sunitinib consolidation can prolong remissions induced by taxane-based chemotherapy in women with metastatic breast cancer. The method involves a two-arm open-label (2:1 randomization) multicenter, randomized phase II trial evaluating the efficacy of sunitinib (arm A) versus no therapy (arm B) in patients with HER-2-negative metastatic breast cancer who achieved an objective response to taxane-based chemotherapy. The results of this study indicates that the primary endpoint of progression-free survival (PFS) ≥5 months was achieved in 10 of 36 patients (28%) in arm A and 4 of 19 patients (21%) in arm B. The median PFS was 2.8 and 3.1 months, respectively. A protocol amendment to the sunitinib dosing schedule was made because 53% (17/32) of patients treated at a starting dose of 50 mg (4 weeks on/2 weeks off) required dose reduction. Changing the starting dose to sunitinib 37.5 mg continuously resulted in dose reductions in 44% (7/16) of patients. Grades III–IV toxicity occurred in 69% of patients in arm A (fatigue 31%, musculoskeletal pain 11%, neutropenia and thrombopenia 8%) and 11% in arm B. The proof-of-principle study does not confirm the hypothesis that sunitinib consolidation therapy can lead to a predefined clinically relevant proportion of patients with PFS of ≥5 months after an objective response to taxanes. Furthermore, toxicity was significant.


Breast cancer Angiogenesis Sunitinib Consolidation Taxanes 



We would like to thank all the participating patients, all the centers who contributed to the study, and Liza Van Eenoo who helped in the coordination of the study and data collection. This study was supported by an unrestricted grant by Pfizer N.V. and used for the performance of this study.

List of recruiting centers and principal investigators: University Hospitals Leuven (Robert Paridaens and Hans Wildiers), Imelda Bonheiden (Wim Wynendaele), AZ St Jan Brugge (Nele Claes), Ziekenhuis Oost Limburg (Jeroen Mebis, Daisy Luyten, Guy Debrock), St-Elisabeth Turnhout (Marc Martens), St-Elisabeth Namen (Peter Vuylsteke and Jean-Charles Goemine), UZ Gent (Hannelore Denys and Veronique Cocquyt), St-Niklaas (Willem Lybaert), Charleroi (Jean-Luc Canon), UZ Brussel (Christel Fontaine and Jacques De Grève), CHC-Liège (Drs C. Focan, MP Graas, F. Kreutz), CHU Sart Tilman Liège (Guy Jerusalem), and Clinique St-pierre Ottignies (Lionel Duck).

Conflict of interest



  1. 1.
    Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26(11):1810–1816CrossRefPubMedGoogle Scholar
  2. 2.
    George S, Blay JY, Casali PG et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45(11):1959–1968CrossRefPubMedGoogle Scholar
  3. 3.
    Gennari A, Amadori D, De LM et al (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24(24):3912–3918CrossRefPubMedGoogle Scholar
  4. 4.
    Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592CrossRefPubMedGoogle Scholar
  5. 5.
    Davidson NG (1996) Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 23(5 Suppl 11):6–10PubMedGoogle Scholar
  6. 6.
    Gianni L, Munzone E, Capri G et al (1995) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87(15):1169–1175CrossRefPubMedGoogle Scholar
  7. 7.
    Fountzilas G, Athanassiadis A, Kalogera-Fountzila A et al (1997) Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer 33(11):1893–1895CrossRefPubMedGoogle Scholar
  8. 8.
    Vici P, Di LL, Conti F et al (1997) Paclitaxel activity in anthracycline refractory breast cancer patients. Tumori 83(3):661–664PubMedGoogle Scholar
  9. 9.
    Seidman AD, Tiersten A, Hudis C et al (1995) Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13(10):2575–2581PubMedGoogle Scholar
  10. 10.
    Ravdin PM, Burris HA III, Cook G et al (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13(12):2879–2885PubMedGoogle Scholar
  11. 11.
    Valero V, Jones SE, Von Hoff DD et al (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16(10):3362–3368PubMedGoogle Scholar
  12. 12.
    Paridaens R, Biganzoli L, Bruning P et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European organization for research and treatment of cancer randomized study with cross-over. J Clin Oncol 18(4):724–733PubMedGoogle Scholar
  13. 13.
    Sargent DJ, Chan V, Goldberg RM (2001) A three-outcome design for phase II clinical trials. Control Clin Trials 22(2):117–125CrossRefPubMedGoogle Scholar
  14. 14.
    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124CrossRefPubMedGoogle Scholar
  15. 15.
    Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239CrossRefPubMedGoogle Scholar
  16. 16.
    Harbeck N, Chan A, ten Bokkel Huinink D et al. (2009) No clinical evidence for increase in tumour malignant potential in patients (Pts) with metastatic breast cancer (mBC) treated with bevacizumab (BV) and docetaxel (D) in the phase III AVADO study. San Antonio Breast Cancer Symposium; abstract no. 6089Google Scholar
  17. 17.
    Stessels F, Van den Eynden G, Van der Auwera I et al (2004) Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 90(7):1429–1436CrossRefPubMedGoogle Scholar
  18. 18.
    Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676CrossRefPubMedGoogle Scholar
  19. 19.
    Wildiers H, Guetens G, De BG et al (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88(12):1979–1986CrossRefPubMedGoogle Scholar
  20. 20.
    Cobleigh MA, Langmuir VK, Sledge GW et al (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(5 Suppl 16):117–124CrossRefPubMedGoogle Scholar
  21. 21.
    Bergh J, Greil R, Voytko N, Makhson A, Cortes J, Lortholary A, Huang X, Giogettie C, Kern KA, Lichinitser M (2010) Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). Proc Am Soc Clin Oncol. LBA1010Google Scholar
  22. 22.
    Crown J, Dieras V, Staroslawska E, Yardley DA, Davidson N, Bachelot TD, Tassell VR, Huang X, Kern KA, Romieu G (2010) Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). Proc Am Soc Clin Oncol. LBA1011Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • H. Wildiers
    • 1
  • C. Fontaine
    • 2
  • P. Vuylsteke
    • 3
  • M. Martens
    • 4
  • J. L. Canon
    • 5
  • W. Wynendaele
    • 6
  • C. Focan
    • 7
  • J. De Greve
    • 2
  • P. Squifflet
    • 8
  • R. Paridaens
    • 1
  1. 1.Department of General Medical Oncology/Multidisciplinary Breast CentreUniversity Hospitals LeuvenLeuvenBelgium
  2. 2.Department of Medical OncologyOncologisch Centrum, UZBrusselBrusselsBelgium
  3. 3.Department of OncologySint-Elisabeth HospitalNamurBelgium
  4. 4.Department of Oncology-RadiologySint-Elisabeth HospitalTurnhoutBelgium
  5. 5.Department of Oncology-Hematology and RadiologyGrand Hopital de CharleroiCharleroiBelgium
  6. 6.Department of Oncology-RadiotherapyImelda HospitalBonheidenBelgium
  7. 7.Department of Oncology-Hemato-ImmunologyCHC HospitalLiègeBelgium
  8. 8.IDDILouvain-la-NeuveBelgium

Personalised recommendations